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Abstract
Background: Despite recognition of the importance of timely presentation to HIV care, research on pathways to
care is lacking. The adverse impact of depression upon adherence to antiretroviral therapy is established. There is
emerging evidence to suggest depression may inhibit initial engagement with care. However, the effect of
depression and other psychosocial factors upon the pathway to care is unknown.
Methods: We used mixed methods to explore pathways to care of people accessing testing and treatment in Goa,
India. Questionnaires including measures of common mental disorder, hazardous alcohol use, cognition and
assessment of pathways to care (motivations for testing, time since they were first aware of this reason for testing,
whether they had been advised to test, who had given this advice, time elapsed since this advice was given) were
administered to 1934 participants at the time of HIV testing. Qualitative interviews were carried out with 15 study
participants who attended the antiretroviral therapy treatment centre. Interview topic guides were designed to
elicit responses that discussed barriers and facilitators of accessing testing and care.
Results: Pathways were often long and complex. Quantitative findings revealed that Common Mental Disorder was
associated with delayed testing when advised by a Doctor (the most common pathway to testing) (AOR = 6.18, 2.
16–17.70). Qualitative results showed that triggers for testing (symptoms believed to be due to HIV, and for women,
illness or death of their husband) suggested that poor health, rather than awareness of risk was a key stimulus for
testing. The period immediately before and after diagnosis was characterised by distress and fear. Stigma was a
prominent backdrop to narratives. However, once participants had made contact with care and support (HIV services
and non-governmental organisations), these systems were often effective in alleviating fear and promoting confidence
in treatment and self-efficacy.
Conclusion: The effectiveness of formal and informal systems of support around the time of diagnosis in supporting
people with mental disorder is unclear. Ways of enhancing these systems should be explored, with the aim of
achieving timely presentation at HIV care for all those diagnosed with the disease.
Background
Early diagnosis and timely treatment can enable people
diagnosed with HIV to live long lives lived largely free
from HIV-related morbidity [1, 2]. Late presentation to
care, defined as presenting with a CD4 count of less than
350 cells/ml or attending care with an AIDS-defining ill-
ness [3], is associated with poor outcomes for individual
patients (increased risk of morbidity, death) as well for
treatment programmes (increased costs) [4]. Although
CD4 counts at the time of initiating Antiretroviral Therapy
(ART) have improved over time within many individual
programmes, a recent systematic review of aggregated data
from African studies showed no change in CD4 counts be-
tween 2002 and 2013 [5]. Ensuring pathways to testing and
care are short and direct, ie. testing and diagnosis prior to
the onset of HIV/AIDS-related illness, presentation at HIV
care promptly after diagnosis, and ART initiated as soon as
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eligibility criteria are met, is an important component of
working towards an AIDS-free generation [6].
Although studies looking at pathways to care are com-
mon in psychiatry [7, 8], we were unable to identify any
studies that examined pathways to HIV testing and care.
Despite the body of evidence regarding the risks associ-
ated with late presentation, our understanding of why
people might delay testing for HIV and/or linkage to
care until they are very sick is limited. Although innova-
tions in HIV services, such as provider-initiated testing,
provision within primary care etc. have reduced systems
level barriers to testing and treatment, service-level bar-
riers cannot be completely eliminated [9–11]. Likewise,
economic constraints, associated with the prioritisation
of basic needs for food, accommodation, clothing over
healthcare [12] have been suggested as potentially im-
portant barriers to timely testing and care [13]. Stigma
has been identified as an important deterrent to timely
testing and treatment uptake [14, 15].
Depression and heavy alcohol use are known to be as-
sociated morbidity and mortality and sub-optimal adher-
ence to ART [16–19]. The role of alcohol in determining
pathways to care and timing of presentation to care is
unclear [20, 21]. A recent study in South Africa found
that those with poor emotional health were more likely
to be late presenters [12]. In our study in Goa (Umeed),
we found that those with depressive symptoms were less
likely to collect HIV test results and less likely to attend
care [22]. However, the role of common psychological
morbidities and other psychosocial factors in the earlier
stages of the continuum of care (pathways to testing, initi-
ating contact with Antiretroviral Therapy (ART) services)
is largely unexplored.
In order to understand how these and other factors
might contribute to late presentation, it is necessary to
better understand peoples’ pathways from before they
undergo HIV testing, through to receiving their diagno-
sis, initiating care and starting ART.
Methods
Design
Findings presented here come from analysis of baseline
quantitative and nested qualitative data from the Umeed
cohort study carried out in Goa, India [22–24]. The overall
aim of Umeed was to investigate the impact of common
mental disorders, hazardous alcohol use and cognitive im-
pairment upon access to HIV testing and care. The Umeed
cohort consisted of 1934 participants, recruited at the time
of coming for HIV testing and followed up for a minimum
of 1 month to ascertain whether those who tested positive
had linked to HIV care. We analysed baseline quantitative
data and qualitative interviews with a purposive sample of
HIV-positive participants accessing treatment and care for
HIV to address the following aims.
Study aims
a) To describe the pathways to care of cohort
participants
b) to examine the role of common mental disorder,
hazardous alcohol use and cognitive impairment in
determining pathways
c) to explore the role of other psychosocial factors in
shaping the experience of accessing HIV testing and
care.
Setting
Goa is an Indian state with a population of 1.34 million
(Government of Goa 2010, https://www.goa.gov.in/know-
goa/aboutgoa.html, accessed 23 September 2010). For the
purposes of HIV/AIDS surveillance, Goa is divided into
two districts: at the time of data collection, the north
was one of India’s high prevalence districts, with more
than one percent prevalence among women attending
for antenatal care. The south was medium prevalence,
with a high prevalence among high-risk groups (more
than five percent among those attending STI clinics)
(United Nations General Assembly Special Session 2008,
http://data.unaids.org/pub/Report/2008/india_2008_coun-
try_progress_report_en.pdf, accessed 23 May 2010). The
study was located at Goa Medical College (GMC), the
only tertiary level hospital in the state and home to the
sole public ART Treatment Centre in Goa. GMC is cen-
trally located on a main road and bus routes just outside
of the state capital, Panjim.
Participants
The cohort was recruited from attendees of the Inte-
grated Counselling and Testing Centre (ICTC). Partici-
pants were recruited between January 2008 and January
2010 and followed-up until March 2010, at the time of
attending the ICTC for pre-test counselling and testing.
Participants were either: “walk-in” clients (self-referrals, or
primary care physician referrals) or those formally referred
for testing by doctors from other GMC departments.
Those attending for the first time, for pre-test counselling
and a HIV blood test, and who spoke Konkani, Hindi, or
English were eligible to participate. Participants were
eligible for the qualitative study if they had: a) collected
test results and attended the ART Centre; b) agreed to
be approached after collection of test results about partici-
pation in the qualitative study (at the time of consent to
participate in the quantitative study). Researchers asked
attendees of the ART Centre whether they had partici-
pated in the quantitative study. Participants were asked
for their Patient Identification (PID) number (unique iden-
tifier assigned by ICTC Counsellors). This was linked to
study identification numbers. Those participants who had
agreed to being approached were provided with further
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information about the qualitative study and asked to sign a
second consent form, using the same procedures as at
baseline. Purposive sampling was carried out to select par-
ticipants with a range of characteristics that were expected
to affect their experience of testing and accessing services
for HIV/AIDS (gender, time since diagnosis, symptoms of
Common Mental Disorder (CMD), Alcohol Use Disorder
(AUD) and cognitive impairment).
Quantitative measures
Questionnaires were administered by research assistants
to participants at the time of attendance for HIV-testing.
Questions relating to sociodemographic characteristics,
HIV-related behaviours, beliefs and knowledge (trans-
mission and prevention knowledge, disclosure plans,
sexual behaviour, knowledge and symptoms of sexually
transmitted infections) and a screening assessment for
mental, substance and alcohol use disorders and cogni-
tive testing were included. Basic sociodemographic data
was collected from those who declined to participate.
CMD was measured using the nine item Patient
Health Questionnaire (PHQ-9), the seven item General-
ised Anxiety Disorder scale (GAD-7), and the panic dis-
order module [25]. The PHQ-9 has been previously
validated in Goa, for the detection of CMD in primary
care, being one of five instruments to achieve an area
under the curve (AUC) from receiver operating character-
istic analysis of at least 0 · 80 (0 · 84 for the PHQ-9) [26].
The 10-item Alcohol Use Disorder Identification Test
(AUDIT) was used to screen for hazardous and dependent
alcohol use [27]. The instrument has been widely used
in India [28] and in Goa [29]. Two measures of cogni-
tive functioning were included: word list learning (asses-
sing memory) and animal naming (measuring verbal
fluency, an aspect of executive functioning, known to be
a common deficit in people living with HIV/AIDS [30].
A full description of questionnaires, including mental
health and cognition measures can be found elsewhere in
our open access paper [23].
Pathways to care: Given the lack of literature on path-
ways to HIV care at the time of study design, our path-
ways to care questionnaire was devised specifically for
use in this study, with reference to the pathways to psy-
chiatric care literature (eg. [31]). Participants were asked
to indicate their motivations for testing from a list of op-
tions developed from formative qualitative interviews
with local non-governmental organisation (NGO) and
ICTC, ART Centre staff. Options included in the final
questionnaire were: pre-marital testing; test in prepar-
ation for working abroad; having a child or partner who
was HIV-positive; partner’s risk behaviour; symptoms
believed to be due to HIV; risk behaviour. For each of
the motivations indicated, participants were asked to es-
timate the time elapsed since they first became aware of
this reason for testing (less than 1 week; more than a
week but less than a month; more than a month but less
than a year; more than a year). Next, participants were
asked to identify any persons who had advised them to
undergo testing for HIV (ie. Doctor, NGO staff member,
family member, friend) and estimate the length of time
elapsed since this advice was received (less than 1 week;
more than a week but less than a month; more than a
month but less than a year; more than a year).
Qualitative interviews
Fifteen interviews were carried out in local languages by
two Research Assistants trained in social science and
with experience of qualitative interviewing. Topic guides
for interviews were developed with the aim of investigat-
ing psychosocial barriers and facilitators of HIV testing
and accessing care for HIV/AIDS. Participants were
asked to reflect on their attitudes, thoughts, feelings and
responses (actions) at different time-points in their path-
way to the ART Centre. Interviews began by exploring
the period before testing. Participants were asked about
their motivations for testing and factors that had encour-
aged or discouraged testing. Interviews examined experi-
ences of pre-test counselling and testing and post-test
counselling and attending the ART Centre, including in-
teractions with clinic staff. Interviews lasted between 30
and 40 min and were carried out at the ART Centre or
in private interview cabins at the ICTC (according to the
preference of the participant).
Data analysis
Our hypothesis was that CMD, AUD and cognitive im-
pairment would be independently associated with longer
pathways to care, ie. More time elapsed between a) first
awareness of motivations for testing and attending the
ICTC for testing b) being advised to test and attending
the ICTC for testing. In the testing of both hypotheses,
we moved from bivariate (chi-squared tests for homo-
geneity and crude odds ratios) to multivariable analyses
(logistic regression) controlling for the effects of gender,
education and age. Due to the negligible prevalence of
AUD among women (0·9 %), all analyses of alcohol use
were carried out using a men-only sample (n = 915).
We analysed the qualitative data using thematic
analysis to develop a coding framework and identify emer-
ging themes. Two of the researchers (RM, AL) read the
first five qualitative interviews repeatedly to immerse
themselves in the data. Using NVIVO software, RM and
AL labelled meaningful pieces of text with appropriate
codes and sub-codes. The two independent sets of codes
were compared and amalgamated into a single framework.
Emergent themes were discussed. RM applied the coding
framework to the full dataset and reconciled the final
themes.
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Results
Quantitative
There was strong evidence to support an association be-
tween CMD and delaying testing to after 1 month of be-
ing advised by a Doctor and weaker evidence to suggest
a similar association with being advised to test by an
NGO staff member (AOR = 6.18, 95 % CI = 2.16–17.70;
OR = 56.0, 95 % CI = 1.93–1.62e + 03, respectively) (Table 1).
There was some evidence to suggest that CMD was
associated with delaying coming to test after knowing
about partner’s risk. In bivariate analyses, CMD was
found to be inversely associated with reporting repeat
testing (OR = 0.2, 95 % CI = 0.28–0.96). Although the
magnitude of this association altered little after adjusting
for gender, education and age, it was no longer statistically
significant (AOR = 0.55, 95 % CI = 0.30–1.03). CMD was
also associated with reporting risk behaviour as a reason
for testing (AOR = 3.04, 95 % CI = 1.68–5.41). AUD was
associated with not giving a reason for testing (AOR =
1.68, 95 % CI = 1.25–2.27) and reporting risk behaviour as
a reason for testing (AOR = 1.95, 95 % CI = 1.16–3.27).
There was evidence to suggest that low score on the
delayed recall test was inversely associated with delaying
testing to after 1 month of being aware of symptoms
that may be due to HIV (AOR= 0.22, 95 % CI = 0.05–0.96)
(Table 2). Low score on the test of verbal fluency was in-
versely associated with delaying testing for more than
1 month after being aware of risk behaviour (AOR = 0.22,
95 % CI = 0.08–0.57). There was weak evidence that low
score on the test of delayed recall was associated with
delaying testing for more than 1 month after being advised
by a family member, friend or person other than a Doctor/
NGO worker (OR = 2.81, 95 % CI = 0.80–9.95; AOR = 2.68,
95 % CI = 0.69–10.42). Low score on the delayed recall
cognitive test was inversely associated with testing before
going abroad (AOR = 0.11, 95 % CI = 0.01–0.79). In bivari-
ate analysis, there was weak evidence of an association be-
tween low score on the delayed recall test and having a
HIV-positive partner or child (OR = 1.42, 95 % CI = 0.94–
2.14); however, after adjusting for potential confounders,
this association reached statistical significance (AOR =
1.31, 95 % CI = 1.06–1.62). Low score on the verbal fluency
test was associated with having a child or partner who was
living with HIV (AOR= 1.31, 95 % CI = 1.07–1.60).
Qualitative
Pathways to testing were clearly delineated by gender.
Among male participants, symptoms (such as weakness,
weight loss and skin problems) which were taken as a
potential sign of HIV, were a common trigger for initiating
the pathway for testing.
“I had come to the skin department..I was getting
small, small boils in my mouth so I had come to see
the Doctor that time- I felt that I should go and do the
HIV test…” (#1269)
Among men, other triggers for testing included their
wives being tested (at antenatal care or at the time of
giving birth) and in one case, a wife’s presentation at
hospital with symptoms of TB. For women, their hus-
band’s illness or death due to HIV-related causes was
the most common impetus for testing.
Participants reported undertaking multiple tests. For
example, one male interviewee described initially being
tested around 4 months after his wife tested positive for
TB and HIV. He then attended GMC for testing and re-
ceived a positive diagnosis but “did not take the report
from them- I lost my paper”. He described not returning
for testing until he started experiencing symptoms (around
6 to 7 months later). After not feeling well whilst visiting
his village and subsequently being told to test for HIV by a
Doctor, one male participant reported undertaking four
tests with inconsistent results prior to the final positive test
at GMC. This participant described his anger with Doctors
when they had suggested testing and told him he was in-
fected with HIV. At the time of recruitment to the qualita-
tive study, he had disengaged from HIV services and was
attending the ART Centre with his wife so that she could
complete her CD4 count.
The role of stigma
Internalised stigma and anticipated discrimination emerged
as clear themes in participant narratives, with a distinct
impact upon pathways to testing and care. Internalised
stigma prevented the disclosure of HIV test results.
Participants feared repercussions for themselves and
their family members:
“I did not tell anyone about this sickness. I did not speak
about this sickness to anyone because I feel disgrace
about it and if my co-worker come to know that I am
HIV positive then they will keep distant from me” (#1117)
Participants described their fear of meeting others
from their communities whilst visiting the ART Centre,
since “only those who are positive come here”. At the
same time, the value of ART in enabling being able to
live “normally” and being perceived to be doing so were
key facilitators of accessing care:
“I had a skin infection- big lumps all over my body.
Then Doctor gave me these tablets and all the
infection went. From that day I have energy for doing
work and I can earn some more money. Now nobody
can say I have this disease- even my company Doctor
does not know it. From looking at me nobody can say I
was sick.” (#1067)
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Table 1 Associations between reason for testing, length of time aware of risk, route to testing and CMD/AUD
Reason for testing, length of time
aware of risk, route to testing
All CMD P-value
(chi-squared)
OR (95 % CI) aAOR (95 % CI) bAUD P-value
(chi-squared)
OR (95 % CI) aAOR (95 % CI)
No reason given 1095 (56.6) 51 (6.1) 0.23 1.27 (0.86–1.89) 133 (32.8) <0.01 1.68 (1.2–2.26) 1.68 (1.25–2.27)
Pre-marital test 29 (1.5) 2 (6.9) 0.88 1.31 (0.31–5.58) 4 (20.0) 0.47 0.67 (0.22–2.02)
Repeat test 378 (19.5) 12 (3.2) 0.03 0.52 (0.28–0.96) 0.55 (0.30–1.03) 57 (30.7) 0.22 1.24 (0.87–1.77)
Test before going abroad 30 (1.6) 1 (3.3) 0.81 0.60 (0.08–4.47) 9 (34.6) 0.38 1.44 (0.63–3.28)
Child/partner who is HIV + ve 119 (6.2) 7 (5.9) 0.80 1.11 (0.50–2.44) 8 (30.8) 0.67 1.20 (0.52–2.80)
Known for <1 month 47 (39.5) 2 (4.3) 1 (16.7)
Known for >1 month 72 (60.5) 5 (6.9) 0.54 1.68 (0.31–9.12) 7 (35.0) 0.11 (2.62) 4.95 (0.57–43.04)
Partner’s risk behaviour 91 (4.7) 6 (6.6) 0.60 1.26 (0.54–2.95) 11 (39.3) 0.14 1.77 (0.82–3.85)
Known for <1 month 37 (40.7) 0 (0.0) 4 (33.3) 4 (36.4)
Known for >1 month 54 (59.3) 6 (11.1) 0.04 NA NA 6 (37.5) 7 (63.6) 1.56 (0.32–7.64)
Symptoms which you believe may be due to HIV 77 (4.0) 8 (10.4) 0.05 2.13 (0.99–4.55) 2.26 (1.03–4.96) 18 (34.6) 0.21 1.46 (0.81–2.63)
Known for <1 month 47 (61.0) 2 (4.3) 14 (38.9)
Known for >1 month 30 (39.0) 6 (20.0) 0.03 5.63 (0.99–32.12) 15.53 (1.53–157.68) 4 (25.0) 0.33 0.52 (0.14–2.00)
Risk behaviour 112 (5.8) 15 (13.4) <0.01 3.01 (1.68–5.41) 3.04 (1.67–5.55) 28 (41.8) 0.01 2.05 (1.23–3.42) 1.95 (1.16–3.27)
Known for <1 month 60 (53.6) 6 (10.0) 13 (35.1)
Known for >1 month 52 (46.4) 9 (17.3) 0.26 1.88 (0.62–5.77) 15 (50.0) 0.22 1.85 (0.68–5.03
Advised to test by Doctor 1457 (75.3) 84 (5.8) 0.19 1.40 (0.85–2.30) 166 (28.0) 0.44 1.13 (0.83–1.54
<1 month ago 1433 (98.4) 79 (5.5) 164 (28.0)
>1 month ago 24 (1.7) 5 (20.8) <0.01 4.51 (1.63–2.44) 6.18 (2.16–17.70) 2 (22.2) 0.70 0.73 (0.15–3.57
Advised to test by NGO staff 60 (3.1) 3 (5.0) 0.90 0.92 (0.28–3.00) 16 (?)
<1 month ago 58 (95.1) 2 (3.5) 16 (6.6)
>1 month ago 3 (4.9) 2 (66.7) <0.01 56.00 (1.93–1.624e + 03) NA 0 (0.0) NA NA
Advised to test by family member/friend/other 71 (3.7) 1 (1.4) 0.13 0.24 (0.03–1.78)
<1 month 47 (66.2) 1 (2.1) 3 (15.0)
>1 month ago 24 (33.8) 1 (0.0) 0.47 NA 3 (21.4) 0.63 1.55 (0.25–9.38)
aAdjusted for gender, education, age
bAnalysed using a men-only dataset, n = 915
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Table 2 Associations between reason for testing, length of time aware of risk, route to testing and cognitive impairment (delayed recall and verbal fluency) among people
attending for HIV testing in Goa, India (n = 1934)
Reason for testing Low score-
delayed recall
P-value
(chi-squared)
OR (95 % CI) aAOR (95 % CI) Low score-
verbal fluency
P-value
(chi-squared)
OR (95 % CI) aAOR (95 % CI)
No reason given 258 (23.6) 0.55 0.94 (0.76–1.16 280 (25.6) 0.79 1.03 (0.84–1.27
Pre-marital test 4 (13.8) 0.36 0.53 (0.18–1.53) 6 (20.7) 0.57 0.75 (0.30–1.84)
Repeat test 80 (21.2) 0.45 0.87 (0.66–1.15) 91 (24.1) 0.47 0.89 (0.68–1.16)
Test before going abroad 1 (3.3) 0.01 0.11 (0.02–0.84) 0.11 (0.01–0.79) 7 (23.3) 0.56 0.87 (0.37–2.04)
Length of time aware of risk
Child/partner who is HIV + ve 35 (29.4) 0.09 1.42 (0.94–2.14) 1.31 (1.06–1.62) 42 (35.3) 0.02 1.62 (1.09–2.39) 1.31 (1.07–1.60)
Known for <1 month 14 (29.8) 14 (29.8)
Known for >1 month 21 (29.2) 0.94 0.97 (0.43–2.18) 28 (38.9) 0.31 1.50 (0.68–3.31)
Partner’s risk behaviour 26 (28.6) 0.20 1.36 (0.85–2.16) 27 (29.7) 0.39 1.22 (0.77–1.94)
Known for <1 month 11 (29.7) 13 (35.1)
Known for >1 month 15 (27.8) 0.84 0.91 (0.36–2.30) 14 (25.9) 0.35 0.65 (0.26–1.62)
Symptoms which you believe
may be due to HIV
18 (23.4) 0.95 1.02 (0.59–1.75) 21 (27.3) 0.77 1.08 (0.65–1.80)
Known for <1 month 14 (29.8) 14 (29.8)
Known for >1 month 4 (13.3) 0.10 0.36 (0.10–1.27) 0.22 (0.05–0.96) 7 (23.3) 0.54 0.72 (0.25–2.07)
Risk behaviour 28 (25.0) 0.62 1.12 (0.72–1.74) 36 (32.1) 0.12 1.39 (0.92–2.09)
Known for <1 month 19 (31.7) 26 (43.3)
Known for >1 month 9 (17.3) 0.08 0.45 (0.18–1.13) 0.29 (0.10–0.83) 10 (19.2) 0.01 0.31 (0.13–0.76) 0.22 (0.08–0.57) P < 0.01
Route to testing
Advised to test by Doctor 339 (23.3) 0.71 1.05 (0.82–1.34) 363 (24.9) 0.10 0.82 (0.65–1.04) 0.82 (0.64–1.04)
<1 month ago 334 (23.3) 358 (25.0) 0.24
>1 month ago 5 (20.8) 0.78 0.87 (0.32–2.34) 5 (20.8) 0.64 0.79 (0.29–2.13)
Advised to test by NGO staff 22 (36.7) 0.70 0.58 (0.03–9.98) 32 (53.3) 0.14 NA
<1 month ago 22 (37.9) 32 (55.2)
>1 month ago 0 (0.0) 0.18 NA 0 (0.0) 0.06 NA
Advised to test by family
member/friend/other
??
<1 month 6 (12.8) 14 (29.8)
>1 month ago 7 (29.2) 0.09 2.81 (0.80–9.95) 2.68 (0.69–10.42) 9 (37.5) 0.51 1.41 (0.50–4.03)
aAdjusted for gender, education, age
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Barriers and facilitators to attendance for HIV testing
Participants generally had a good grasp of basic facts
about HIV prior to testing, eg. they understood it to be
a potentially fatal condition and had an awareness of the
ways in which it could (and could not) be transmitted.
However, their own risk of contracting HIV was gener-
ally perceived to be low, therefore testing occurred only
in the context of a secondary trigger such as symptoms
or the illness or the death of a partner. For women in
particular, a positive test result was often inexplicable, as
their own fidelity was perceived to be protective:
“I was so scared… why? You know I never had a
sexual relationship with anyone besides my husband.
My husband died.... I don’t know how he got HIV. He
used to drink alcohol and stay in [another part of
Goa] for work- I got it from him.” (#238)
For some, being advised to have a HIV test (usually by
a Doctor) provided motivation to attend the ICTC, with
the aim of eliminating the possibility of HIV infection:
“’why have they asked me to do the test, what have I
done?’ I felt like that. But now I’ve seen things about
AIDS and all, no? So I thought let me do the test and
take the worry out of my mind.” (#1440)
Two participants specifically mentioned that their
awareness that testing and treatment were available free
of charge was an important facilitator of attending for
testing. Encouragement from healthcare workers was
also reported as effective in instigating testing:
“firstly I met one doctor is here in GMC, Dr. Anjali,
she told me not to be scared whatever problem you
have, you tell. I was having skin infection- my whole
body had lumps, she took me inside, I was so scared
but she told me ‘don’t get scared and sit inside. If
something happened to you then what about your
family? Who will look after them? So go down and get
tested for HIV’”.(#1067)
Participants stated they had been unable to attend for
testing for economic and family-related reasons. For ex-
ample, one participant reported that his work in a hotel
meant that it was not possible for him to come for test-
ing during the busy tourist season. Another stated that a
lack of work meant that he did not have money to travel
and had delayed his visit to the testing centre. Some par-
ticipants attributed delay in their attendance for testing to
sickness or death within the family, which necessitated
travel or care for others.
Fear about test results was reported as a common char-
acteristic of the testing process. Although fear relating to
testing positive was cited as a motivating factor, in some
cases, anxiety was clearly a barrier to accessing services:
“I: so you thought about it and then you came [to the
ICTC] after 4 weeks?
R: yes I thought of coming and then I was considering
whether to go or not… go or not… and then at last
I decided to come but still I came here twice and
went back.
I: why did you come and roam around and go back?
R: I was feeling very different- like what would happen,
if I am tested positive then what will happen in the
future? Then family problem also, they will not accept
me, I started thinking of all these things… that’s why I
was considering whether to go for testing or not” (#1117)
Barriers and facilitators of accessing care
In response to a diagnosis of HIV, participants reported
feelings of hopelessness, sometimes including suicidal
ideation. Lack of knowledge about availability of treat-
ment contributed to hopelessness, which led to fatalistic
acceptance of their diagnosis. Among those interviewed,
this was characterised as a distinct period, around the
time of diagnosis which participants transitioned out of,
with the help of support from NGOs, healthcare workers
and family members:
“I: when Doctor told you to do HIV testing, at that
time what thoughts came in your mind?
R: many thoughts came in my mind… like its better off
to be dead- there is no use of living now… after
thinking like that I used to get a lot of tension, so my
wife said ‘now its happened, what to do now? There’s
no use in being tense. It is better to take medicine
whilst you are alive.” (#204)
Support was invaluable in facilitating access to care.
This often took the form of advice giving and en-
couragement from friends, family members and
healthcare workers. Services and support provided by
NGOs (eg. accompanying people to appointments,
guiding people through processes, providing informa-
tion, particularly about treatment, provision of food
rations and health insurance schemes) were cited as
being particularly important:
“First I went to […] to see one private doctor to
show them my skin infection… that doctor sent me
to Goa Medical College for testing and he gave me
a note… I met Zindagi Goa’ people there [at Goa
Medical College] they have helped me a lot.
Whenever I feel tense Zindagi Goa always helped
me.” (#1067)
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Those participants who had been very sick at the time
of testing positive, recognised the role of the referral
pathway between government testing centres and one of
the two HIV care homes in Goa (both run by NGOs) in
restoring them to health.
Needing to support and provide for family members
were often important motivating factors for doing what
was necessary to continue to live:
“My wife loves me a lot and if something happens to
me then who will look after them? So because of my
wife and child I gained a little guts I should live for
them- I am their support, only I support them, I am
their main pillar. Who will look after them? Because
of all these thoughts I am become a little stronger”.
(#1117)
Likewise, belief in the efficacy of medication, instilled
by healthcare workers and bolstered by demonstrable
impact, was an important facilitator of continuing to ac-
cess care:
“Now she, my wife, she is good [healthy after being
diagnosed with HIV and taking ART]… Doctor told
me she is good…if you take medicine you’ll be feeling
good like her. Now see after taking medicine, looking
at me, nobody can say I got HIV- I am fine now”.
(#1067)
Discussion
Pathways to HIV testing were often long and complex.
Triggers for testing (symptoms believed to be due to
HIV, and for women, illness or death of their husband)
were a response to sickness rather than awareness of risk
and therefore suggestive of late presentation. Quantitative
findings showed that CMD increased the possibility of
delayed testing. Pathways were often characterised by a
period of fear and low mood immediately before and
after diagnosis, which was commonly allayed through the
provision of information about treatment and support from
family members/friends, healthcare and NGO workers. The
reduction of symptoms associated with starting ART and
the return to normal roles that this facilitated was associ-
ated with further alleviation of distress.
Worryingly, although participants were often aware of
symptoms and the need for testing, this did not neces-
sarily lead to immediate testing; participants might wait
until there was another reason for visiting the hospital
or until symptoms had worsened. This finding is consist-
ent with the results of a systematic review of qualitative
studies from sub-Saharan Africa which suggested that
while awareness of risk provided a background motivation
to test, testing was “undertaken when there was a clear de-
cline in health which necessitates access to health care”
[32]. Further evidence of poor health as a key stimulus for
testing was supported by the inverse association of low
scores for delayed recall with late help-seeking triggered
by symptoms. A possible explanation for this finding is
that it is those who are most unwell with HIV-related ill-
nesses who perform poorly on cognitive tests [23, 33] and
who therefore attend for testing without further delay.
CMD was associated with increased odds of a delay of
more than 1 month between being told by Doctor or
NGO worker to test for HIV and attendance for testing.
This finding is consistent with our previous results that
showed: a) CMD inhibited attendance for post-test
counselling; b) symptoms of anxiety and depression were
associated with non-attendance at the ART Centre [22].
Our results demonstrate that CMD may have an inhibi-
tory impact earlier in the pathway testing, prior to attend-
ance for testing. Fear of AIDS (perceived as synonymous
with sickness and death) was linked to the anticipated
impact of a HIV diagnosis upon ability to perform a social
role (relations with families, communities, economic prod-
uctivity). These concerns have been found to be a barrier
to HIV testing and associated with late presentation at care
[34, 35]. The impact of emotional distress around the time
of diagnosis on pathways to care and HIV outcomes
is unclear. The relationship between fear and distress
and CMD is also uncertain. It should be noted, however,
that in our study, some participants described successfully
overcoming their fears and sense of hopelessness to access
testing and care.
Internalised stigma and fear of discrimination formed
a backdrop to qualitative narratives: inhibiting acknow-
ledgment of risk, contributing to fear of being seen acces-
sing HIV services and limiting access to sources of support
by preventing disclosure. Evidence from elsewhere suggests
a strong bi-directional link between depression and
internalised stigma [36, 37]. The exact nature of the re-
lationship between these two factors and how their
interaction impacts upon engagement with care warrants
further exploration.
When interpreting our findings, it is important to be
aware of how the nature of our qualitative sample (those
attending the ART Centre) may have influenced our
findings. Although participants universally reported bar-
riers to accessing HIV testing and care, their inclusion in
our sample demonstrates that they had been, to a large
extent, successful in overcoming these. Unfortunately,
interviewing those who had dropped out of care was
outside of the scope of the current project. Our sample
may therefore be selected for resilience: our findings
are likely to be skewed towards facilitators. The most
vulnerable groups (those who did not collect test results,
those who failed to attend the ART Centre after diagnosis)
are excluded. This may explain why some factors found to
be important elsewhere, ie. Financial constraints, did not
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feature strongly in our narratives. It will be important to
carry out similar research in future with those who drop
out from care. In the context of our mixed methods co-
hort study, interviewer resources were limited. We antici-
pated that a sample of 15 would enable us to get close to
saturation regarding the main topics of interest. However,
it is possible that a larger sample would have facilitated
the emergence of additional themes. Unfortunately,
validation of the pathways to care tool was outside of the
scope of the Umeed study. Despite these limitations, given
the dearth of evidence on pathways to HIV testing and
care, our study is an important initial contribution to the
evidence base.
Conclusions
Our findings suggest that in Goa, people often delay
accessing HIV testing and care until they experience un-
deniable symptoms, forcing them to face their fears and
undergo testing. Whilst mental distress related to diag-
nosis may play a role in delaying access to care, this was
often remedied through support from health services,
NGOs, families and friends. Once contact with care and
support (HIV services or NGOs) was established, these
systems seemed to be effective in mitigating fear and
promoting confidence in treatment and self-efficacy. The
effectiveness of these systems in supporting people with
mental disorder is unclear and should be explored.
Screening followed by specific interventions to support
people with depression to engage with care may help to
shorten pathways and limit drop-out. Likewise, it is im-
portant to design research to explore the best ways to
combat stigma and other barriers to early diagnosis and
care, to shorten and simplify pathways to care, in order
to ensure people living with HIV are able to derive max-
imum benefits from treatment.
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